Log in

NASDAQ:INFIInfinity Pharmaceuticals Stock Price, Forecast & News

0.00 (-0.10 %)
(As of 06/4/2020 04:00 PM ET)
Today's Range
Now: $0.89
50-Day Range
MA: $0.99
52-Week Range
Now: $0.89
Volume185,800 shs
Average Volume161,239 shs
Market Capitalization$51.12 million
P/E RatioN/A
Dividend YieldN/A
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreements with Arcus Biosciences, Inc. and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Read More
Infinity Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:INFI



Sales & Book Value

Annual Sales$3.05 million
Book Value$0.14 per share


Net Income$-47,060,000.00
Net Margins-3,308.31%


Market Cap$51.12 million
Next Earnings Date8/4/2020 (Estimated)

Receive INFI News and Ratings via Email

Sign-up to receive the latest news and ratings for INFI and its competitors with MarketBeat's FREE daily newsletter.

Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions

How has Infinity Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Infinity Pharmaceuticals' stock was trading at $1.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, INFI stock has decreased by 11.9% and is now trading at $0.8901. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Infinity Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Infinity Pharmaceuticals.

When is Infinity Pharmaceuticals' next earnings date?

Infinity Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Infinity Pharmaceuticals.

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) announced its earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.06. The biotechnology company had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.25 million. Infinity Pharmaceuticals had a negative net margin of 3,308.31% and a negative return on equity of 329.49%. View Infinity Pharmaceuticals' earnings history.

What price target have analysts set for INFI?

4 equities research analysts have issued twelve-month price objectives for Infinity Pharmaceuticals' shares. Their forecasts range from $1.00 to $3.00. On average, they expect Infinity Pharmaceuticals' share price to reach $2.17 in the next twelve months. This suggests a possible upside of 143.4% from the stock's current price. View analysts' price targets for Infinity Pharmaceuticals.

Has Infinity Pharmaceuticals been receiving favorable news coverage?

News stories about INFI stock have been trending extremely negative this week, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Infinity Pharmaceuticals earned a daily sentiment score of -5.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutInfinity Pharmaceuticals.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 33,300 shares, a decline of 8.0% from the April 30th total of 36,200 shares. Based on an average trading volume of 160,500 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the shares of the company are sold short. View Infinity Pharmaceuticals' Current Options Chain.

Who are some of Infinity Pharmaceuticals' key competitors?

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), ImmunoGen (IMGN), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), AVEO Pharmaceuticals (AVEO) and Bausch Health Companies (BHC).

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the following people:
  • Ms. Adelene Q. Perkins, Chairman & CEO (Age 59)
  • Dr. Lawrence E. Bloch, Pres & Treasurer (Age 53)
  • Dr. Jeffery L. Kutok, Sr. VP & Chief Scientific Officer (Age 52)
  • Mr. Seth A. Tasker, VP, Gen. Counsel & Sec. (Age 40)
  • Ms. Melissa Hackel, VP of Fin.

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

Who are Infinity Pharmaceuticals' major shareholders?

Infinity Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (1.03%) and Bleichroeder LP (0.00%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Bvf Partners L P/Il, Jeffery Kutok and Value Fund L P Biotechnology. View institutional ownership trends for Infinity Pharmaceuticals.

Which major investors are selling Infinity Pharmaceuticals stock?

INFI stock was sold by a variety of institutional investors in the last quarter, including Bleichroeder LP, and Acadian Asset Management LLC. View insider buying and selling activity for Infinity Pharmaceuticals.

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $0.89.

How big of a company is Infinity Pharmaceuticals?

Infinity Pharmaceuticals has a market capitalization of $51.12 million and generates $3.05 million in revenue each year. The biotechnology company earns $-47,060,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Infinity Pharmaceuticals employs 25 workers across the globe.

What is Infinity Pharmaceuticals' official website?

The official website for Infinity Pharmaceuticals is www.infi.com.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.